FDA
-
-
-
-
-
-
-
Agenus’ BOT/BAL Achieves 42% Two-Year Survival in Refractory MSS CRC, Advances Toward Registration with FDA Alignment on Phase 3
-
-
-
-
-
-
-
Agenus Inc. (AGEN) PT Lowered to $7 at H.C. Wainwright
-
-
-
-
-
-
-
Jefferies Downgrades Agenus Inc. (AGEN) to Hold
-
-
-
-
-
-
-
Nature Medicine Reports Agenus’ Novel Immunotherapy Demonstrates Clinical Activity Against a Deadly Form of Colorectal Cancer on the Rise in Americans Under 50
-
-
-
-
-
-
-
Agenus (AGEN) Reports Updated Phase 1 Data and Progress on BOT/BAL Development
-
-
-
-
-
-
-
Agenus' (AGEN) SaponiQx Announces Breakthrough in Scaling Up of STIMULON Cultured Plant Cell Adjuvant
-
-
-
-
-
-
-
Agenus (AGEN) Receives Fast Track Designation for Botensilimab and Balstilimab in Colorectal Cancer
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

